Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Prashant D Tailor, Timothy T Xu, Blake H Fortes, Raymond Iezzi, Timothy W Olsen, Matthew R Starr, Sophie J Bakri, Brittni A Scruggs, Andrew J Barkmeier, Sanjay V Patel, Keith H Baratz, Ashlie A Bernhisel, Lilly H Wagner, Andrea A Tooley, Gavin W Roddy, Arthur J Sit, Kristi Y Wu, Erick D Bothun, Sasha A Mansukhani, Brian G Mohney, John J Chen, Michael C Brodsky, Deena A Tajfirouz, Kevin D Chodnicki, Wendy M Smith, Lauren A Dalvin
OBJECTIVE: To determine the appropriateness of ophthalmology recommendations from an online chat-based artificial intelligence model to ophthalmology questions. PATIENTS AND METHODS: Cross-sectional qualitative study from April 1, 2023, to April 30, 2023. A total of 192 questions were generated spanning all ophthalmic subspecialties. Each question was posed to a large language model (LLM) 3 times. The responses were graded by appropriate subspecialists as appropriate, inappropriate, or unreliable in 2 grading contexts...
March 2024: Mayo Clin Proc Digit Health
#2
JOURNAL ARTICLE
Jing Li, Thomas A Hilimire, Liu Yueying, Lili Wang, Jiaxin Liang, Balázs Győrffy, Vitali Sikirzhytski, Hao Ji, Li Zhang, Chen Cheng, Xiaokai Ding, Kendall R Kerr, Charles E Dowling, Alexander A Chumanevich, Zachary T Mack, Gary P Schools, Chang-Uk Lim, Leigh Ellis, Xiaolin Zi, Donald C Porter, Eugenia V Broude, Campbell McInnes, George Wilding, Michael B Lilly, Igor B Roninson, Mengqian Chen
Mediator kinases CDK19 and CDK8, pleiotropic regulators of transcriptional reprogramming, are differentially regulated by androgen signaling but both kinases are upregulated in castration-resistant prostate cancer (CRPC). Genetic or pharmacological inhibition of CDK8 and CDK19 reverses the castration-resistant phenotype and restores the sensitivity of CRPC xenografts to androgen deprivation in vivo. Prolonged CDK8/19 inhibitor treatment combined with castration not only suppresses the growth of CRPC xenografts but also induces tumor regression and cures...
March 28, 2024: Journal of Clinical Investigation
#3
JOURNAL ARTICLE
Mark A Davison, Daniel T Lilly, Arpan A Patel, Ahmed Kashkoush, Xiaoying Chen, Wei Wei, Edward C Benzel, Richard A Prayson, Samuel Chao, Lilyana Angelov
PURPOSE: Primary treatment of spinal ependymomas involves surgical resection, however recurrence ranges between 50 and 70%. While the association of survival outcomes with lesion extent of resection (EOR) has been studied, existing analyses are limited by small samples and archaic data resulting in an inhomogeneous population. We investigated the relationship between EOR and survival outcomes, chiefly overall survival (OS) and progression-free survival (PFS), in a large contemporary cohort of spinal ependymoma patients...
March 4, 2024: Journal of Neuro-oncology
#4
JOURNAL ARTICLE
Laila A Gharzai, Emily Morris, Krithika Suresh, Phuc Felix Nguyen-Tân, David I Rosenthal, Maura L Gillison, Paul M Harari, Adam S Garden, Shlomo Koyfman, Jimmy J Caudell, Christopher U Jones, Darrion L Mitchell, Greg Krempl, John A Ridge, Michael F Gensheimer, James A Bonner, Edith Filion, Neal E Dunlap, William A Stokes, Quynh-Thu Le, Pedro Torres-Saavedra, Michelle Mierzwa, Matthew J Schipper
BACKGROUND: The increased incidence of human papillomavirus (HPV)-related cancers has motivated efforts to optimise treatment for these patients with excellent prognosis. Validation of surrogates for overall survival could expedite the investigation of new therapies. We sought to evaluate candidate intermediate clinical endpoints in trials assessing definitive treatment of p16-positive oropharyngeal cancer with chemotherapy or radiotherapy. METHODS: We did a retrospective review of five multicentre, randomised trials (NRG/RTOG 9003, 0129, 0234, 0522, and 1016) that tested radiotherapy with or without chemotherapy in patients (aged ≥18 years) with p16-positive localised head or neck squamous-cell carcinomas...
March 2024: Lancet Oncology
#5
JOURNAL ARTICLE
Alexander Villalobos, Howard Hussein Dabbous, Olivia Little, Olumide Babajide Gbolahan, Mehmet Akce, Meghan Allegra Lilly, Zachary Bercu, Nima Kokabi
To evaluate the safety and efficacy of combining yttrium-90 radioembolization (Y90-RE) with immune checkpoint inhibitor therapy, consecutive advanced unresectable hepatocellular carcinoma (HCC) patients treated between 2016 and 2022 with atezolizumab/bevacizumab or nivolumab within three-months pre- and post-Y90-RE were retrospectively evaluated. Tumor response and treatment-related clinical/laboratory adverse events (AE) were assessed at 1 and 6 months, as well as differences in clinical and laboratory variables and median overall survival (OS) from initial treatment (whether it was Y90-RE or systemic therapy) between the two cohorts...
November 25, 2023: Current Oncology
#6
Ariana M Familiar, Anahita Fathi Kazerooni, Hannah Anderson, Aliaksandr Lubneuski, Karthik Viswanathan, Rocky Breslow, Nastaran Khalili, Sina Bagheri, Debanjan Haldar, Meen Chul Kim, Sherjeel Arif, Rachel Madhogarhia, Thinh Q Nguyen, Elizabeth A Frenkel, Zeinab Helili, Jessica Harrison, Keyvan Farahani, Marius George Linguraru, Ulas Bagci, Yury Velichko, Jeffrey Stevens, Sarah Leary, Robert M Lober, Stephani Campion, Amy A Smith, Denise Morinigo, Brian Rood, Kimberly Diamond, Ian F Pollack, Melissa Williams, Arastoo Vossough, Jeffrey B Ware, Sabine Mueller, Phillip B Storm, Allison P Heath, Angela J Waanders, Jena V Lilly, Jennifer L Mason, Adam C Resnick, Ali Nabavizadeh
Pediatric brain and spinal cancers remain the leading cause of cancer-related death in children. Advancements in clinical decision-support in pediatric neuro-oncology utilizing the wealth of radiology imaging data collected through standard care, however, has significantly lagged other domains. Such data is ripe for use with predictive analytics such as artificial intelligence (AI) methods, which require large datasets. To address this unmet need, we provide a multi-institutional, large-scale pediatric dataset of 23,101 multi-parametric MRI exams acquired through routine care for 1,526 brain tumor patients, as part of the Children's Brain Tumor Network...
October 2, 2023: ArXiv
#7
JOURNAL ARTICLE
Reiko Matsuzawa, Masahiro Morise, Kentaro Ito, Osamu Hataji, Kosuke Takahashi, Junji Koyama, Yachiyo Kuwatsuka, Yasuhiro Goto, Kazuyoshi Imaizumi, Hidetoshi Itani, Teppei Yamaguchi, Yoshitaka Zenke, Masahide Oki, Makoto Ishii
BACKGROUND: Immune checkpoint inhibitors (ICI) plus platinum-based chemotherapy has been recognized as a standard first-line therapy in non-small cell lung cancer (NSCLC); however, no prospective clinical trials of docetaxel (DTX) plus ramucirumab (RAM) following first-line ICI plus platinum-based chemotherapy has been reported. METHODS: In this multicentre, open-label, single-arm, phase 2 trial, we enrolled patients with NSCLC from eight centres in Japan. Patients with metastatic NSCLC with disease progression after platinum-based chemotherapy plus ICI were eligible for the study...
December 2023: EClinicalMedicine
#8
JOURNAL ARTICLE
Tycel Phillips, Nicholas Liu, Brian Bloudek, Kristen Migliaccio-Walle, Jade Reynolds, John M Burke
BACKGROUND: A 2010 study on the impact of cancer mortality on productivity costs found Hodgkin lymphoma to have the second largest productivity cost lost per death in the United States. The ECHELON-1 trial demonstrated that frontline brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) improves overall survival (OS) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in stage III/IV classical Hodgkin lymphoma (cHL), reducing the risk of death to 41% (hazard ratio = 0.59; 95% CI = 0...
November 3, 2023: Journal of Managed Care & Specialty Pharmacy
#9
JOURNAL ARTICLE
Jessie Signorelli, Thuy Tran, Marie E Sirek, Yarelis Díaz-Rohena, Jodi L Taraba, Benyam Muluneh, Nayanika Basu, Jennifer Lilly, Julianne Darling
INTRODUCTION: To date, there is no adherence estimator to identify risk of nonadherence prior to initiating oral oncolytics. METHODS: A workgroup was assembled through the National Community Oncology Dispensing Association and tasked with creating a tool to meet this need. Tool constructs were defined after a review of the literature identifying top barriers to adherence. A second literature search was conducted to identify questions targeting specific barriers from validated adherence questionnaires...
October 30, 2023: Journal of Oncology Pharmacy Practice
#10
RANDOMIZED CONTROLLED TRIAL
Julien Hadoux, Rossella Elisei, Marcia S Brose, Ana O Hoff, Bruce G Robinson, Ming Gao, Barbara Jarzab, Pavel Isaev, Katerina Kopeckova, Jonathan Wadsley, Dagmar Führer, Bhumsuk Keam, Stéphane Bardet, Eric J Sherman, Makoto Tahara, Mimi I Hu, Ravinder Singh, Yan Lin, Victoria Soldatenkova, Jennifer Wright, Boris Lin, Patricia Maeda, Jaume Capdevila, Lori J Wirth
BACKGROUND: Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in advanced RET -mutant medullary thyroid cancer in a phase 1-2 trial, but its efficacy as compared with approved multikinase inhibitors is unclear. METHODS: We conducted a phase 3, randomized trial comparing selpercatinib as first-line therapy with the physician's choice of cabozantinib or vandetanib (control group). Eligible patients had progressive disease documented within 14 months before enrollment...
November 16, 2023: New England Journal of Medicine
#11
JOURNAL ARTICLE
Joshua A Shapiro, Krutika S Gaonkar, Stephanie J Spielman, Candace L Savonen, Chante J Bethell, Run Jin, Komal S Rathi, Yuankun Zhu, Laura E Egolf, Bailey K Farrow, Daniel P Miller, Yang Yang, Tejaswi Koganti, Nighat Noureen, Mateusz P Koptyra, Nhat Duong, Mariarita Santi, Jung Kim, Shannon Robins, Phillip B Storm, Stephen C Mack, Jena V Lilly, Hongbo M Xie, Payal Jain, Pichai Raman, Brian R Rood, Rishi R Lulla, Javad Nazarian, Adam A Kraya, Zalman Vaksman, Allison P Heath, Cassie Kline, Laura Scolaro, Angela N Viaene, Xiaoyan Huang, Gregory P Way, Steven M Foltz, Bo Zhang, Anna R Poetsch, Sabine Mueller, Brian M Ennis, Michael Prados, Sharon J Diskin, Siyuan Zheng, Yiran Guo, Shrivats Kannan, Angela J Waanders, Ashley S Margol, Meen Chul Kim, Derek Hanson, Nicholas Van Kuren, Jessica Wong, Rebecca S Kaufman, Noel Coleman, Christopher Blackden, Kristina A Cole, Jennifer L Mason, Peter J Madsen, Carl J Koschmann, Douglas R Stewart, Eric Wafula, Miguel A Brown, Adam C Resnick, Casey S Greene, Jo Lynne Rokita, Jaclyn N Taroni
Pediatric brain and spinal cancers are collectively the leading disease-related cause of death in children; thus, we urgently need curative therapeutic strategies for these tumors. To accelerate such discoveries, the Children's Brain Tumor Network (CBTN) and Pacific Pediatric Neuro-Oncology Consortium (PNOC) created a systematic process for tumor biobanking, model generation, and sequencing with immediate access to harmonized data. We leverage these data to establish OpenPBTA, an open collaborative project with over 40 scalable analysis modules that genomically characterize 1,074 pediatric brain tumors...
July 12, 2023: Cell Genom
#12
JOURNAL ARTICLE
Thorsten H Ecke, Christina J Meisl, Thorsten Schlomm, Anja Rabien, Flora Labonté, Dezhi Rong, Sebastian Hofbauer, Frank Friedersdorff, Lilli Sommerfeldt, Nella Gagel, Andreas Gössl, Dimitri Barski, Thomas Otto, Camilla M Grunewald, Günter Niegisch, Martin J P Hennig, Mario W Kramer, Stefan Koch, Jenny Roggisch, Steffen Hallmann, Sarah Weiß, Michael Waldner, Johannes Graff, Elke Veltrup, Friederike Linden, Roland Hake, Sebastian Eidt, Ralph M Wirtz
INTRODUCTION AND OBJECTIVE: BTA stat®, NMP22® BladderChek®, UBC® Rapid Test, and CancerCheck® UBC® rapid VISUAL are urinary-based rapid tests. This multicenter study is the first study comparing all available rapid tests on a large cohort of bladder cancer patients and healthy controls in one setting. METHODS: In total 732 urine samples (second morning urine) in a real-world assessment have been analyzed. We evaluated clinical samples from 464 patients with histologically confirmed urothelial tumors of the urinary bladder (17 solitary CIS, 189 low-grade, 187 high-grade nonmuscle invasive, 71 high-grade muscle invasive), 77 patients with No Evidence of Disease (NED), and from 191 healthy controls...
July 3, 2023: Urologic Oncology
#13
MULTICENTER STUDY
Matthew R Smith, Shahneen Sandhu, Daniel J George, Kim Nguyen Chi, Fred Saad, Antoine Thiery-Vuillemin, Olaf Stàhl, David Olmos, Daniel C Danila, Rustem Gafanov, Elena Castro, Helen Moon, Anthony M Joshua, Gary E Mason, Byron M Espina, Yan Liu, Angela Lopez-Gitlitz, Peter Francis, Katherine B Bevans, Karim Fizazi
BACKGROUND: Niraparib is a highly selective poly (adenosine diphosphateribose) polymerase-1 and poly (adenosine diphosphate-ribose) polymerase-2 inhibitor indicated for select patients with ovarian, fallopian tube, and primary peritoneal cancer. The phase 2 GALAHAD trial (NCT02854436) demonstrated that niraparib monotherapy is tolerable and efficacious in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations, particularly those with breast cancer gene ( BRCA ) alterations who had progressed on prior androgen signaling inhibitor therapy and taxane-based chemotherapy...
July 2023: Journal of Managed Care & Specialty Pharmacy
#14
REVIEW
Nikhil Sharma, Arka N Mallela, Diana D Shi, Lilly W Tang, Hussam Abou-Al-Shaar, Zachary C Gersey, Xiaoran Zhang, Samuel K McBrayer, Kalil G Abdullah
Isocitrate dehydrogenase (IDH) is a key enzyme in normal metabolism and homeostasis. However, mutant forms of IDH are also defining features of a subset of diffuse gliomas. In this review, we highlight current techniques targeting IDH-mutated gliomas and summarize current and completed clinical trials exploring these strategies. We discuss clinical data from peptide vaccines, mutant IDH (mIDH) inhibitors, and PARP inhibitors. Peptide vaccines have the unique advantage of targeting the specific epitope of a patient's tumor, inducing a highly tumor-specific CD4+ T-cell response...
2023: Neuro-oncology advances
#15
JOURNAL ARTICLE
Hilde M Buiting, Femke Botman, Lilly-Ann van der Velden, Linda Brom, Florien van Heest, Eva E Bolt, Pieter de Mol, Ton Bakker
AIM: To explore (1) experiences of primary care physicians (PCPs) and oncological medical specialists about providing care to patients living longer with incurable cancer, and (2) their preferences concerning different care approaches (palliative support, psychological/survivorship care support). BACKGROUND: At present, oncological medical specialists as well as PCPs are exploring how to improve and better tailor care to patients living longer with incurable cancer...
April 28, 2023: Primary Health Care Research & Development
#16
REVIEW
Lilly W Tang, Arka N Mallela, Hansen Deng, Timothy E Richardson, Shawn L Hervey-Jumper, Samuel K McBrayer, Kalil G Abdullah
Models for human gliomas prove critical not only to advancing our understanding of glioma biology but also to facilitate the development of therapeutic modalities. Specifically, creating lower-grade glioma (LGG) models has been challenging, contributing to few investigations and the minimal progress in standard treatment over the past decade. In order to reliably predict and validate the efficacies of novel treatments, however, LGG models need to adhere to specific standards that recapitulate tumor genetic aberrations and micro-environment...
2023: Frontiers in Oncology
#17
JOURNAL ARTICLE
Zhishuo Wei, Diego D Luy, Shalini Jose, Hansen Deng, Sila Yavan, Stephen Worrell, J Raouf Belkhir, Lilly W Tang, Ajay Niranjan, L Dade Lunsford
BACKGROUND: Stereotactic radiosurgery (SRS) is a widely accepted treatment modality for brain metastases. The role of SRS in patients with higher numbers of metastases remains controversial. OBJECTIVES: To define outcomes in patients with ≥20 brain metastases managed using single-session SRS. METHODS: This single-institution retrospective cohort study studied 75 patients (26 non-small-cell lung cancer, 21 small-cell lung cancer, 14 breast cancer, and 14 melanoma) undergoing single-session SRS...
April 5, 2023: Neurosurgery
#18
JOURNAL ARTICLE
Zhishuo Wei, Diego D Luy, Lilly W Tang, Hansen Deng, Shalini Jose, Sydney Scanlon, Ajay Niranjan, L Dade Lunsford
OBJECTIVE: This study aims to evaluate the efficacy of stereotactic radiosurgery (SRS) in improving health outcomes of patients with gynecologic brain metastases. METHODS: Patients with gynecologic metastases treated with SRS from 2008 to 2020 were retrospectively reviewed. The median age at SRS was 63 years old (cervical 45.5, endometrial 65.5, ovarian 61). The median number of tumors was 3 (range 1-27), and cumulative tumor volume was 2.33 cc (range 0...
March 14, 2023: Gynecologic Oncology
#19
JOURNAL ARTICLE
Zhishuo Wei, Matthew Pease, Lilly W Tang, Hansen Deng, Regan Shanahan, Andrew Faramand, Ajay Niranjan, L Dade Lunsford
PURPOSE: To assess survival and neurological outcomes for patients who underwent primary or salvage stereotactic radiosurgery (SRS) for infratentorial juvenile pilocytic astrocytomas (JPA). METHODS: Between 1987 and 2022, 44 patients underwent SRS for infratentorial JPA. Twelve patients underwent primary SRS and 32 patients underwent salvage SRS. The median patient age at SRS was 11.6 years (range, 2-84 years). Prior to SRS, 32 patients had symptomatic neurological deficits, with ataxia as the most common symptom in 16 patients...
March 2023: Journal of Neuro-oncology
#20
JOURNAL ARTICLE
John M Burke, Kristina S Yu, Uche Mordi, Brian Bloudek, Nicholas Liu, Tycel Phillips
BACKGROUND: The ECHELON-2 5-year update showed continued clinically meaningful improvements in progression-free survival (PFS) and overall survival with frontline (1L) A+CHP (brentuximab vedotin in combination with cyclophosphamide, doxorubicin, prednisone) vs CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in CD30-expressing peripheral T-cell lymphomas (PTCLs). OBJECTIVE: To estimate PTCL annual prevalence in the United States in 2031 without and with A+CHP using data from the ECHELON-2 5-year update...
March 2023: Journal of Managed Care & Specialty Pharmacy
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
